What Does Rachel Sherman Think About Top FDA Regulatory Issues?
Executive Summary
Speaking at the BIO CEO & Investor Conference, US agency's No. 2 official talks about compassionate use, opioids, clinical trial design, and the agency's succession plan.
You may also be interested in...
Life After FDA: Rachel Sherman To Tackle Real World Evidence, Clinical Trial Efficiency
Sherman, who left the No. 2 post at FDA in January, is working part-time at Duke-Margolis and serving as a consultant to Medidata Solutions.
Swayed By Industry Opposition To 'Intended Use' Rule, FDA Definitively Delays Implementation
US FDA is considering calls to drop 'totality of circumstances' test and to clarify that mere knowledge of unapproved use does not constitute evidence the use was intended.
FDA Deputy On CRLs: 'It's Not Our Property To Release'
US FDA Principal Deputy Commissioner Rachel Sherman said during the BIO CEO & Investor conference that while investors and others would like to see complete response letters, the agency's hands are bound when it comes to their full release. Sherman also commented on FDA's focus for right-to-try legislation.